Surgery: Future directions in multimodality therapy for NSCLC
- PMID: 20029443
- DOI: 10.1038/nrclinonc.2009.174
Surgery: Future directions in multimodality therapy for NSCLC
Abstract
Patients with stage III non-small-cell lung cancer (nSclc) comprise a heterogeneous population; the role of surgical resection in this setting has been controversial. Albain and colleagues recently demonstrated that trimodality therapy with lobectomy had clinical benefit for patients with pathologic nodal N2 stage III nSclc. we discuss the trial and its implications for future lung cancer therapy.
Comment on
-
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24. Lancet. 2009. PMID: 19632716 Free PMC article. Clinical Trial.
Similar articles
-
Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?Expert Rev Anticancer Ther. 2016 Nov;16(11):1131-1144. doi: 10.1080/14737140.2016.1240039. Epub 2016 Oct 6. Expert Rev Anticancer Ther. 2016. PMID: 27654059
-
Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.Thorac Surg Clin. 2008 Nov;18(4):403-15. doi: 10.1016/j.thorsurg.2008.07.004. Thorac Surg Clin. 2008. PMID: 19086609 Review.
-
Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer.J Thorac Dis. 2015 Sep;7(9):1616-23. doi: 10.3978/j.issn.2072-1439.2015.09.07. J Thorac Dis. 2015. PMID: 26543609 Free PMC article.
-
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.Oncologist. 2020 Jun;25(6):e964-e975. doi: 10.1634/theoncologist.2019-0661. Epub 2020 Jan 14. Oncologist. 2020. PMID: 31943520 Free PMC article.
-
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.Cancers (Basel). 2021 Sep 26;13(19):4811. doi: 10.3390/cancers13194811. Cancers (Basel). 2021. PMID: 34638296 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources